The pharmaceutical value chain model depicted in Figure 1 covers a full range of activities that are required to bring a product from conception to final consumer. The key players in the chain are ...
How can I maximise value by using third parties ... Johnathon Marshall is a director of PricewaterhouseCoopers’ Pharmaceutical Supply Chain practice. He can be contacted at + 44 (0)207 804 ...
StockStory.org on MSN10h
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. Companies specializing in drug ...
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the ...
and reduce costs across the pharmaceutical value chain. Pharma 4.0 applies to various stages of the pharmaceutical process, including: Consumers are increasingly looking for transparency in drug ...
With proper data governance, the pharma industry can improve patient-centricity in trials and bring lifesaving therapies to ...
Zydus Lifesciences is working to advance its position in the global pharmaceutical sector by increasing its focus on medical ...
Ron Lanton, Partner, Lanton Law, examines the legal and economic impacts of reciprocal tariffs on the pharma supply chain, including potential disruptions and increased drug costs.
To further enhance the value of the RNN model ... By addressing the scarcity of prior studies on sequential delay issues in pharmaceutical supply chains, this project also contributes valuable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results